Literature DB >> 22443646

Hybrid options for treating cardiac disease.

Ramanan Umakanthan1, Marzia Leacche, David X Zhao, Anna H Gallion, Prabodh C Mishra, John G Byrne.   

Abstract

The options for treating heart disease have greatly expanded during the course of the last 2 1/2 decades with the advent of hybrid technology. The hybrid option for treating cardiac disease implies using the technology of both interventional cardiology and cardiac surgery to treat cardiac disease. This rapidly developing technology has given rise to new and creative techniques to treat cardiac disease involving coronary artery disease, coronary artery disease and cardiac valve disease, and atrial fibrillation. It has also led to the establishment of new procedural suites called hybrid operating rooms that facilitate the integration of technologies of interventional cardiology catheterization laboratories with those of cardiac surgery operating rooms. The development of hybrid options for treating cardiac disease has also greatly augmented teamwork and collaboration between interventional cardiologists and cardiac surgeons. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22443646     DOI: 10.1053/j.semtcvs.2011.12.002

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg        ISSN: 1043-0679


  3 in total

Review 1.  Combining PCI and CABG: the role of hybrid revascularization.

Authors:  Kelly D Green; Donald R Lynch; Tyffany P Chen; David Zhao
Journal:  Curr Cardiol Rep       Date:  2013-04       Impact factor: 2.931

2.  Concurrent Coronary Artery and Valvular Heart Disease - Hybrid Treatment Strategies in 2013.

Authors:  Kendra J Grubb; Tamim Nazif; Mathew R Williams; Isaac George
Journal:  Interv Cardiol       Date:  2013-08

3.  Hybrid coronary revascularization versus off-pump coronary artery bypass grafting and percutaneous coronary intervention for the treatment of two-vessel coronary artery disease with proximal left anterior descending artery stenosis.

Authors:  Jiapei Qiu; Pengxiong Zhu; Zixiong Liu; Hong Xu; Jun Liu; Qiang Zhao
Journal:  J Thorac Dis       Date:  2019-06       Impact factor: 2.895

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.